Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

745.95 -4.82 (-0.64%)
Official Closing Price Updated: 6:30 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,716,788
Open 749.42
Bid (Size) 743.75 (1)
Ask (Size) 746.74 (2)
Prev. Close 750.77
Today's Range 743.77 - 752.20
52wk Range 367.35 - 800.78
Shares Outstanding N/A
Dividend Yield 0.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025. 
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily

Performance

YTD
+25.96%
+25.96%
1 Month
-2.19%
-2.19%
3 Month
+18.61%
+18.61%
6 Month
+22.84%
+22.84%
1 Year
+101.66%
+101.66%

More News

Read More
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Via Benzinga
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
Via InvestorPlace
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
Eli Lilly and Co's Options Frenzy: What You Need to Know
Via Benzinga
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
Via The Motley Fool
Top Research Reports For Eli Lilly, Linde & Caterpillar
Via Talk Markets
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
Via The Motley Fool
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
Via Investor's Business Daily
Nasdaq 100 Forecast: QQQ Inches Higher Ahead Of Fed Speakers
Via Talk Markets
Topics Economy
Exposures Interest Rates
Eli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show
Via Benzinga
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Via InvestorPlace
Topics ETFs
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Via Benzinga
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Via InvestorPlace
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Via Talk Markets
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Via InvestorPlace
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Novo Nordisk Arms Wegovy to Be a Triple Threat
Via MarketBeat
3 Magnificent Stocks That Could Double or More by 2030
Via The Motley Fool
This Vanguard ETF Has Skyrocketed 40% in 12 Months. Is It a No-Brainer Buy Right Now?
Via The Motley Fool
Topics ETFs
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
Via The Motley Fool
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Via Benzinga
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.